X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare SHASUN PHARMA with WYETH LTD - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SHASUN PHARMA vs WYETH LTD - Comparison Results

WYETH LTD 
   Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SHASUN PHARMA WYETH LTD SHASUN PHARMA/
WYETH LTD
 
P/E (TTM) x 123.9 27.7 447.0% View Chart
P/BV x 8.5 5.3 159.5% View Chart
Dividend Yield % 0.2 1.3 18.3%  

Financials

 SHASUN PHARMA   WYETH LTD
EQUITY SHARE DATA
    SHASUN PHARMA
Mar-14
WYETH LTD
Mar-13
SHASUN PHARMA/
WYETH LTD
5-Yr Chart
Click to enlarge
High Rs941,044 9.0%   
Low Rs46818 5.6%   
Sales per share (Unadj.) Rs214.2298.6 71.7%  
Earnings per share (Unadj.) Rs5.357.2 9.3%  
Cash flow per share (Unadj.) Rs15.858.4 27.1%  
Dividends per share (Unadj.) Rs1.0017.00 5.9%  
Dividend yield (eoy) %1.41.8 78.4%  
Book value per share (Unadj.) Rs53.3249.5 21.4%  
Shares outstanding (eoy) m56.6222.72 249.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.33.1 10.5%   
Avg P/E ratio x13.116.3 80.5%  
P/CF ratio (eoy) x4.415.9 27.7%  
Price / Book Value ratio x1.33.7 35.1%  
Dividend payout %18.729.7 63.1%   
Avg Mkt Cap Rs m3,95821,157 18.7%   
No. of employees `000NA0.5 0.0%   
Total wages/salary Rs m2,164400 540.9%   
Avg. sales/employee Rs ThNM13,787.4-  
Avg. wages/employee Rs ThNM813.0-  
Avg. net profit/employee Rs ThNM2,643.3-  
INCOME DATA
Net Sales Rs m12,1276,783 178.8%  
Other income Rs m229353 65.0%   
Total revenues Rs m12,3567,136 173.2%   
Gross profit Rs m1,0091,617 62.4%  
Depreciation Rs m59427 2,231.6%   
Interest Rs m4156 7,547.3%   
Profit before tax Rs m2301,938 11.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0-5 0.0%   
Tax Rs m-73632 -11.5%   
Profit after tax Rs m3021,301 23.2%  
Gross profit margin %8.323.8 34.9%  
Effective tax rate %-31.732.6 -97.0%   
Net profit margin %2.519.2 13.0%  
BALANCE SHEET DATA
Current assets Rs m6,8846,984 98.6%   
Current liabilities Rs m8,4562,056 411.3%   
Net working cap to sales %-13.072.6 -17.8%  
Current ratio x0.83.4 24.0%  
Inventory Days Days6299 62.1%  
Debtors Days Days10824 449.3%  
Net fixed assets Rs m4,970244 2,034.5%   
Share capital Rs m113227 49.9%   
"Free" reserves Rs m2,8755,441 52.8%   
Net worth Rs m3,0205,668 53.3%   
Long term debt Rs m1,81725 7,269.6%   
Total assets Rs m13,3477,901 168.9%  
Interest coverage x1.6353.3 0.4%   
Debt to equity ratio x0.60 13,642.8%  
Sales to assets ratio x0.90.9 105.8%   
Return on assets %5.416.5 32.5%  
Return on equity %10.022.9 43.6%  
Return on capital %13.334.0 39.1%  
Exports to sales %46.40.2 21,246.6%   
Imports to sales %14.236.3 39.2%   
Exports (fob) Rs m5,62215 37,983.1%   
Imports (cif) Rs m1,7282,465 70.1%   
Fx inflow Rs m5,84315 38,438.2%   
Fx outflow Rs m2,1732,677 81.2%   
Net fx Rs m3,669-2,662 -137.8%   
CASH FLOW
From Operations Rs m398923 43.1%  
From Investments Rs m-1,635317 -515.9%  
From Financial Activity Rs m1,309-481 -272.1%  
Net Cashflow Rs m71759 9.4%  

Share Holding

Indian Promoters % 39.2 0.0 -  
Foreign collaborators % 0.0 51.1 -  
Indian inst/Mut Fund % 3.6 11.3 31.9%  
FIIs % 17.6 7.2 244.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 39.6 30.4 130.3%  
Shareholders   20,750 21,978 94.4%  
Pledged promoter(s) holding % 12.3 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SHASUN PHARMA With:   CIPLA  PFIZER  NATCO PHARMA  AUROBINDO PHARMA  PIRAMAL ENTERPRISES  

Compare SHASUN PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Nifty Crosses 11,500-Mark; L&T Surges 4% on Buyback News(09:30 am)

Asian stock markets are higher today as Japanese and Hong Kong shares show gains. The Nikkei 225 is up 0.2% while the Hang Seng is up 0.7%.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

This is a Must-Have Stock for Your Portfolio(The 5 Minute Wrapup)

Aug 8, 2018

Tanushree just released the permanent wealth blueprint report. This report includes three safe and steady stocks. I like one in particular. Here's why

Trading in These Times: 8% Gains in 3 Days!(Profit Hunter)

Aug 9, 2018

Here are 2 stocks you can buy right now! And there are plenty more opportunities to come...

Only on WhatsApp, a Weaker Rupee Means a Weaker India(Vivek Kaul's Diary)

Aug 16, 2018

While dollar crossing Rs 70 will have its repercussions, the world isn't exactly coming to an end.

Why HDFC Equity Fund Disappointed Its Investors(Outside View)

Aug 9, 2018

Though popular, HDFC Equity Fund is not among the best performers anymore. Here is the reason behind its underperformance that has left investors disappointed.

HDFC AMC Makes 65% Listing Gains! Should It Attract Mutual Fund Investors?(Outside View)

Aug 8, 2018

PersonalFN explains if investors should invest in schemes of HDFC Mutual Fund looking at the listing gains of HDFC AMC.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SHASUN PHARMA SHARE PRICE


Nov 17, 2015 (Close)

TRACK SHASUN PHARMA

  • Track your investment in SHASUN PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SHASUN PHARMA 8-QTR ANALYSIS

COMPARE SHASUN PHARMA WITH

MARKET STATS